Geron Corporation (GERN) reported fourth quarter EPS of ($0.06) after close Tuesday, compared to the consensus estimate of $0.17. Revenues decreased 20.9% from last year to $178K. Analysts expected revenues of $35.35 million. The stock is now down $0.01 to $2.95 on 2.17 million shares.
Net loss for 2014 was $35.7 million, or $0.23 per share, compared to $38.4 million, or $0.30 per share, for 2013.
On valuation measures, Geron Corp. shares, which currently have an average 3-month trading volume of 2.8 million shares, trade with a P/E to growth ratio of (5.25). Currently ticker boasts 2 ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.
Profitability-wise, GERN has a t-12 operating margin of (3,012%). The $465.34 million market cap company reported $170.06 million in cash vs. $0 in debt in its most recent quarter.
GERN currently prints a one year loss of about 33% and a year-to-date loss of around 7%.
The chart below shows where the equity has traded over the last 52 weeks.
Geron Corp. is a clinical stage biopharmaceutical firm focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.